Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients.

Heide J, Ribback S, Klatte T, Shariat S, Burchardt M, Dombrowski F, Belldegrun AS, Drakaki A, Pantuck AJ, Kroeger N.

World J Urol. 2019 Sep 13. doi: 10.1007/s00345-019-02930-4. [Epub ahead of print]

PMID:
31520111
2.

Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.

Faiena I, Astrow SH, Elashoff DA, Jain R, Bot A, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A.

Cancer Immunol Immunother. 2019 May;68(5):743-751. doi: 10.1007/s00262-019-02316-w. Epub 2019 Feb 21.

PMID:
30790015
3.

Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma.

Steven A, Leisz S, Fussek S, Nowroozizadeh B, Huang J, Branstetter D, Dougall WC, Burchardt M, Belldegrun AS, Seliger B, Pantuck A, Kroeger N.

Urol Oncol. 2018 Nov;36(11):502.e15-502.e24. doi: 10.1016/j.urolonc.2018.07.013. Epub 2018 Aug 28.

PMID:
30170981
4.

Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.

Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):78.e21-78.e28. doi: 10.1016/j.urolonc.2017.09.030. Epub 2017 Nov 8.

PMID:
29128421
5.

Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.

Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):79.e19-79.e26. doi: 10.1016/j.urolonc.2017.10.009. Epub 2017 Nov 2.

PMID:
29103965
6.

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.

Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N.

Urol Oncol. 2017 Feb;35(2):39.e1-39.e7. doi: 10.1016/j.urolonc.2016.09.006. Epub 2016 Oct 26.

PMID:
28341495
7.

Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.

Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K.

Urol Oncol. 2017 May;35(5):272-278. doi: 10.1016/j.urolonc.2016.11.019. Epub 2017 Jan 3.

PMID:
28065395
8.

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS.

JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419.

9.

Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study.

Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Said J, Raman SS, Holden S, Pantuck A, Belldegrun AS, Chamie K.

Urology. 2017 Jan;99:270-277. doi: 10.1016/j.urology.2016.09.039. Epub 2016 Oct 5.

PMID:
27720772
10.

Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.

Donin NM, Pantuck A, Klöpfer P, Bevan P, Fall B, Said J, Belldegrun AS, Chamie K.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1326-32. doi: 10.1158/1055-9965.EPI-16-0226. Epub 2016 Jul 14.

11.

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2170-5. doi: 10.1073/pnas.1525735113. Epub 2016 Feb 10.

12.

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.

Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ.

Urol Oncol. 2015 May;33(5):204.e25-33. doi: 10.1016/j.urolonc.2015.02.013. Epub 2015 Mar 29.

PMID:
25823535
13.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

14.

The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma.

Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, Shariat SF, Belldegrun AS, Klatte T.

Urol Oncol. 2015 Feb;33(2):68.e1-7. doi: 10.1016/j.urolonc.2014.08.005. Epub 2014 Sep 16.

PMID:
25240758
15.

Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff.

Pignot G, Bigot P, Bernhard JC, Bouliere F, Bessede T, Bensalah K, Salomon L, Mottet N, Bellec L, Soulié M, Ferrière JM, Pfister C, Drai J, Colombel M, Villers A, Rigaud J, Bouchot O, Montorsi F, Bertini R, Belldegrun AS, Pantuck AJ, Patard JJ.

Urol Oncol. 2014 Oct;32(7):1024-30. doi: 10.1016/j.urolonc.2014.03.012. Epub 2014 Jul 2.

PMID:
24996775
16.

The contemporary role on surgery in the management of renal masses.

Kroeger N, Belldegrun AS, Pantuck AJ.

World J Urol. 2014 Jun;32(3):571-2. doi: 10.1007/s00345-014-1290-9. No abstract available.

PMID:
24718636
17.

The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation.

Klatte T, Kroeger N, Zimmermann U, Burchardt M, Belldegrun AS, Pantuck AJ.

World J Urol. 2014 Jun;32(3):597-605. doi: 10.1007/s00345-014-1284-7. Epub 2014 Apr 4. Review.

PMID:
24700308
18.

Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α.

Kroeger N, Seligson DB, Signoretti S, Yu H, Magyar CE, Huang J, Belldegrun AS, Pantuck AJ.

Eur J Cancer. 2014 May;50(8):1531-40. doi: 10.1016/j.ejca.2014.01.031. Epub 2014 Feb 21.

PMID:
24565854
19.

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF.

Anticancer Res. 2013 Aug;33(8):2997-3004.

PMID:
23898052
20.

Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma.

de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, Klatte T.

J Urol. 2013 Dec;190(6):1999-2004. doi: 10.1016/j.juro.2013.06.082. Epub 2013 Jul 2.

PMID:
23831313
21.

Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience.

Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS.

Cancer J. 2013 May-Jun;19(3):189-96. doi: 10.1097/PPO.0b013e318292e8a4.

PMID:
23708063
22.

Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data.

Kroeger N, Belldegrun AS, Pantuck AJ.

Evid Based Complement Alternat Med. 2013;2013:701434. doi: 10.1155/2013/701434. Epub 2013 Mar 26. Erratum in: Evid Based Complement Alternat Med. 2013;2013:870454. N, Kroeger [corrected to Kroeger, Nils]; A S, Belldegrun [corrected to Belldegrun, A S]; A J, Pantuck [corrected to Pantuck, A J].

23.

The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma.

Rampersaud EN, Klatte T, Bass G, Patard JJ, Bensaleh K, Böhm M, Allhoff EP, Cindolo L, De La Taille A, Mejean A, Soulie M, Bellec L, Christophe Bernhard J, Pfister C, Colombel M, Belldegrun AS, Pantuck AJ, George D.

Urol Oncol. 2014 Jan;32(1):30.e9-13. doi: 10.1016/j.urolonc.2012.10.012. Epub 2013 Feb 17.

PMID:
23422777
24.

Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.

Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J.

J Immunother. 2013 Feb;36(2):102-11. doi: 10.1097/CJI.0b013e31827bec97.

25.

Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.

Kroeger N, Klatte T, Chamie K, Rao PN, Birkhäuser FD, Sonn GA, Riss J, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2013 Apr 15;119(8):1547-54. doi: 10.1002/cncr.27947. Epub 2013 Jan 18.

26.

Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.

Klatte T, Kroeger N, Rampersaud EN, Birkhäuser FD, Logan JE, Sonn G, Riss J, Rao PN, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2012 Dec 1;118(23):5777-82. doi: 10.1002/cncr.27607. Epub 2012 May 17.

27.

Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.

Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Eur Urol. 2012 May;61(5):888-95. doi: 10.1016/j.eururo.2012.01.012. Epub 2012 Jan 18.

PMID:
22269604
28.

Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma.

Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS.

BJU Int. 2012 Jun;109(11):1600-6. doi: 10.1111/j.1464-410X.2011.10785.x. Epub 2012 Jan 5.

29.

Systemic therapy for metastatic renal cell carcinoma: a review and update.

Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF.

Rev Urol. 2012;14(3-4):65-78.

30.

Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation.

Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, Rioux-Leclerq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2012 Feb;187(2):418-23. doi: 10.1016/j.juro.2011.10.024. Epub 2011 Dec 15.

PMID:
22177164
31.

Clear cell renal cell carcinoma: multiphasic multidetector CT imaging features help predict genetic karyotypes.

Sauk SC, Hsu MS, Margolis DJ, Lu DS, Rao NP, Belldegrun AS, Pantuck AJ, Raman SS.

Radiology. 2011 Dec;261(3):854-62. doi: 10.1148/radiol.11101508. Epub 2011 Oct 24.

PMID:
22025734
32.

The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.

Finley DS, Shuch B, Said JW, Galliano G, Jeffries RA, Afifi AA, Castor B, Magyar C, Sadaat A, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2011 Dec;186(6):2168-74. doi: 10.1016/j.juro.2011.07.068. Epub 2011 Oct 19.

PMID:
22014797
33.

Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival.

Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2012 Apr 1;118(7):1795-802. doi: 10.1002/cncr.26453. Epub 2011 Aug 25.

34.

Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.

Rampersaud EN Jr, Belldegrun AS.

Eur Urol. 2011 Feb;59(2):301-2. doi: 10.1016/j.eururo.2010.11.009. No abstract available.

PMID:
21414876
35.

Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications.

Finley DS, Belldegrun AS.

Curr Urol Rep. 2011 Jun;12(3):209-15. doi: 10.1007/s11934-011-0182-4. Review.

36.

Tumor biology and prognostic factors in renal cell carcinoma.

Finley DS, Pantuck AJ, Belldegrun AS.

Oncologist. 2011;16 Suppl 2:4-13. doi: 10.1634/theoncologist.2011-S2-04. Review.

37.

Ultrasound-based combination therapy: potential in urologic cancer.

Finley DS, Pouliot F, Shuch B, Chin A, Pantuck A, Dekernion JB, Belldegrun AS.

Expert Rev Anticancer Ther. 2011 Jan;11(1):107-13. doi: 10.1586/era.10.174. Review.

PMID:
21166515
38.

Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance.

Shuch B, Pantuck AJ, Pouliot F, Finley DS, Said JW, Belldegrun AS, Saigal C.

BJU Int. 2011 Aug;108(3):343-8. doi: 10.1111/j.1464-410X.2010.09871.x. Epub 2010 Nov 19.

39.

Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features.

Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2011 Jan;185(1):30-5. doi: 10.1016/j.juro.2010.09.013. Epub 2010 Nov 12.

PMID:
21074210
40.

Immunological therapy in urological malignancy: novel combination strategies.

Finley DS, Pouliot F, Chin AI, Shuch B, Pantuck AJ, Belldegrun AS, Dekernion JB.

Int J Urol. 2011 Feb;18(2):94-101. doi: 10.1111/j.1442-2042.2010.02664.x. Epub 2010 Nov 12. Review.

41.

Contemporary management of renal tumors with venous tumor thrombus.

Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS.

J Urol. 2010 Sep;184(3):833-41; quiz 1235. doi: 10.1016/j.juro.2010.04.071. Review.

PMID:
20643450
42.

Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?

Shuch B, Crispen PL, Leibovich BC, LaRochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML.

BJU Int. 2011 Mar;107(5):724-728. doi: 10.1111/j.1464-410X.2010.09488.x.

43.

Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey.

Zisman A, Patard JJ, Raz O, Klatte T, Haifler M, Mendlovic S, Sandbank J, Belldegrun AS, Lindner A, Leibovici D, Pantuck AJ.

Urology. 2010 Sep;76(3):541-6. doi: 10.1016/j.urology.2010.01.089. Epub 2010 May 21.

PMID:
20494411
44.

Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.

Klatte T, Remzi M, Zigeuner RE, Mannweiler S, Said JW, Kabbinavar FF, Haitel A, Waldert M, de Martino M, Marberger M, Belldegrun AS, Pantuck AJ.

J Urol. 2010 Jul;184(1):53-8. doi: 10.1016/j.juro.2010.03.026. Epub 2010 May 15.

PMID:
20478577
45.

[How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?].

Bigot P, Bernhard JC, Crepel M, Bensalah K, Azzouzi AR, de la Taille A, Salomon L, Tostain J, Ficarra V, Pantuck AJ, Belldegrun AS, Méjean A, Ferrière JM, Pfister C, Albouy B, Colombel M, Zini L, Villers A, Montorsi F, Shariat S, Rioux-Leclercq N, Patard JJ.

Prog Urol. 2010 May;20(5):350-5. doi: 10.1016/j.purol.2010.01.007. Epub 2010 Mar 29. French.

PMID:
20471579
46.

Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome.

Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Garraway I, Wong SG, Belldegrun AS, Pantuck AJ.

J Urol. 2010 Jun;183(6):2403-8. doi: 10.1016/j.juro.2010.01.064. Epub 2010 Apr 18.

PMID:
20403620
47.

Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma.

Klatte T, Anterasian C, Said JW, de Martino M, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2010 Jun;183(6):2143-7. doi: 10.1016/j.juro.2010.02.023.

PMID:
20399450
48.

Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma.

Bernhard JC, Pantuck AJ, Wallerand H, Crepel M, Ferrière JM, Bellec L, Maurice-Tison S, Robert G, Albouy B, Pasticier G, Soulie M, Lopes D, Lacroix B, Bensalah K, Pfister C, Thuret R, Tostain J, De La Taille A, Salomon L, Abbou C, Colombel M, Belldegrun AS, Patard JJ.

Eur Urol. 2010 Jun;57(6):1080-6. doi: 10.1016/j.eururo.2010.02.019. Epub 2010 Feb 19.

49.

Primary and salvage cryotherapy for prostate cancer.

Finley DS, Pouliot F, Miller DC, Belldegrun AS.

Urol Clin North Am. 2010 Feb;37(1):67-82, Table of Contents. doi: 10.1016/j.ucl.2009.11.007. Review.

PMID:
20152521
50.

Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.

Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2010 Feb 1;116(3):616-24. doi: 10.1002/cncr.24768.

Supplemental Content

Loading ...
Support Center